A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 81
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IIEF-EF
Long Form : Index of Erectile Function-Erectile Function
No. Year Title Co-occurring Abbreviation
2020 A Novel Penile Splint as Early Traction Therapy After Grafting Techniques for Peyronie's Disease. ETT, ETT, PD, SPL
2020 Electromagnetic Low-Intensity Extracorporeal Shock Wave Therapy in Patients with Erectile Dysfunction: A Sham-Controlled, Double-Blind, Randomized Prospective Study. ED, EHS, Li-ESWT
2020 Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. ED, EHS, Li-SWT, PDE5i
2020 Low intensity extracorporeal shockwave Therapy shifts PDE5i nonresponders to responders. ED, EFD, EHS, Li-ESWT, MCID
2020 Sexual and ejaculatory function after holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate: a single-center experience. B-TUEP, BPO, HoLEP, LUTS, MSHQ-EJ
2020 Study of phosphodiesterase 5 inhibitors and alpha-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. ABs, BPH, IPSS, LUTS, PDE5i, PVR, QOL
2020 The Daily Therapy With L-Arginine 2,500mg and Tadalafil 5mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study. ED
2020 [Efficacy and safety of low-intensity pulsed ultrasound at different intervals by mechanical force in treating erectile dysfunction: a preliminary study]. ED, EHS, GAQ, LIPUS, MCID, SEAR, SEP, VAS
2019 Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ED, SI, SVP, TAEs
10  2019 Effect of Low-Intensity Extracorporeal Shock Wave on the Treatment of Erectile Dysfunction: A Systematic Review and Meta-Analysis. ED, EHS, Li-ESWT, RCTs
11  2019 Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study. ED, GIC, IELT, PE, PEDT, PEP
12  2019 Is It Compulsory to Investigate for Erectile Dysfunction in Patients Presenting for Low Urinary Tract Symptoms? DCAs, ED, IPSS, LUTS, OR
13  2019 Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction in Diabetic Patients. ED, Li-ESWT, PDE5i, SW
14  2019 Low-intensity shockwave therapy (LiST) for erectile dysfunction: a randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions. ED, EFD, FU, LiST, MCID
15  2019 Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. ED, EHS, Li-ESWT, RCTs
16  2019 Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronie's Disease. OR, PD, SF, SIS
17  2018 Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial. CI, LS
18  2018 Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment. MCIDs, SEP3
19  2018 [Focused low-intensity extracorporeal shock wave therapy for erectile dysfunction: Preliminary observation of 32 cases]. ED, EHS, Li-ESWT
20  2017 An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study. ED, EDITS, ICI, PGE1, QEQ, SQoL
21  2017 Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. RARP, UC
22  2017 Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction-A Double-Blinded, Sham-Controlled, Randomized ClinicalTrial. ED, EHS, LLi-ESWT
23  2017 Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. alpha-blockers, BPH, ED, FDCs, IPSS, LUTS
24  2017 Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis. CI, ED, MD, NSRP, OR, PDE5-Is, RCTs, TEAEs
25  2017 Ethnicity and age as factors in sildenafil treatment of erectile dysfunction. ED, GAQ
26  2017 Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. CI, CNKI, ED, EHS, Li-ESWT, RCTs, RR
27  2017 Treatment response to sildenafil in men with erectile dysfunction relative to concomitant comorbidities and age. ED, MCID
28  2016 A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. CI, ED, GAQ-1, MD, PDE5-Is, RR
29  2016 Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. AMS, BMI, CRP, IPSS, PSA, TRT
30  2016 Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. BNSRP, CI, ED, OR, PDE5, SMD
31  2016 Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. ED, IPSS, LUTS/BPH
32  2016 Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy. EF, NSRP, NSS, OAD
33  2016 Opioids Increase Sexual Dysfunction in Patients With Non-Cancer Pain. CNP, FSFI, SD
34  2015 Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. ED, IIEF, OAD, PBO, PDE5-Is, SEP, SIL, TAD, VAR
35  2015 Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study. ED, LISW
36  2014 A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. ED, PDE5
37  2014 Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups? PDE5, RCTs
38  2014 Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. CPSIQ, DPSIQ, ED
39  2014 Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). CI, DFW, EDT, EF, LS, MCID, NSRP, PDE5-Is, REACTT, SEP-3
40  2014 How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center. BNSRP, ORP, PCa, RARP
41  2014 Medical management of erectile dysfunction in aging males: is it too late to treat? ED, EHS
42  2014 Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men. ED, GAQ, NS-RP, PCa, PDE5-Is, SEP-2, TEAEs
43  2014 Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. CI, ED, LS, MCID, SEP3
44  2014 The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. CI, ED, MD, RR, SEP
45  2014 The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. BPH, ED, IPSS, LUTS, PDE5
46  2013 A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. BMI, RP, UI
47  2013 Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. BII, ED, IPSS, IPSS-QoL, LUTS/BPH, PSA
48  2013 Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. ED, SEP3
49  2013 Retrospective analysis of the efficacy and safety of once-daily tadalafil in patient subgroups: men with mild vs moderate ED and aged <50 vs 50 years. ---
50  2012 Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study. CCI, DSH, ED, PDE5
51  2012 Does kidney transplantation onto the external iliac artery affect the haemodynamic parameters of the cavernosal arteries? EDV, PSV
52  2012 Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. CCI, CVD, ED, OR
53  2012 Response to on-demand vardenafil was improved by its daily usage in hypertensive men. ED, FMD, IMT, LDL, SEP3
54  2012 Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. BII, ED, IPSS, SEP Q3
55  2012 The natural history of penile length after radical prostatectomy: a long-term prospective study. RP
56  2011 Brachial flow-mediated dilation correlates with vardenafil response in hypertensive men with vasculogenic erectile dysfunction. ED, FMD, IMT
57  2011 Stopwatch-assessed duration of erection: a new measure of the efficacy of erectile dysfunction treatments. SEP-3
58  2010 A multicenter, double-blind, placebo-controlled trial to assess the efficacy of sildenafil citrate in men with unrecognized erectile dysfunction. CVD, ED, LUTS
59  2010 A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. ED, LUTS, MR, OAB, QEQ
60  2010 Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. ED, PDE5
61  2010 Efficacy and safety of mirodenafil in men taking antihypertensive medications. ED, GAQ, LSC
62  2010 Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. ED, HDL-C, LDL-C, SEP, TC
63  2010 Inflatable penile prosthesis placement in men with Peyronie's disease and drug-resistant erectile dysfunction: A single-center study. ED, EDITS, IPP, PD
64  2010 Men with mild erectile dysfunction benefit from sildenafil treatment. DBPC, ED, EDITS, GEQs, OL, QEQ
65  2009 Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. BPH, ED, IPSS, LUTS, PVR
66  2008 Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. ED, TSS
67  2008 Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. ED, GAQ, IPSS, IPSS-QOL, LUTS, PVR
68  2008 Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. ED, NSRP, PDE5, SEP
69  2008 Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. AEs, ED
70  2008 Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. ED, GAQ, LS, PDE-5, SEP
71  2008 Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement. BPE, HoLEP, ICIQ-SF, IPSS, NSRRP, PSA
72  2008 Salivary 8-OHdG: a useful biomarker for predicting severe ED and hypogonadism. ED, MOS, OR, SF-36 v2
73  2008 Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. ED
74  2008 Vardenafil in men with stable statin therapy and dyslipidemia. AEs, BMI, ED, LS, PDE-5, SD, SEP
75  2007 Efficacy of vardenafil and influence on self-esteem and self-confidence in patients with severe erectile dysfunction. ED, GAQ
76  2007 Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? BPH, ED
77  2007 The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. ED, LS, PDE-5, SEP, TSS
78  2007 The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. ED, GAQ
79  2007 The Treatment Satisfaction Scale (TSS) is a sensitive measure of treatment effectiveness for both patients and partners: results of a randomized controlled trial with vardenafil. ED, LOCF, LS, mSLQQ-QoL, TSS
80  2006 Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. ED, EQS, GAQ, GCQ, SEP3
81  2005 Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial. ED, GAQ, SEP